Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Hyman Muss, MD, Linberger Cancer Center at the University of North Carolina, Chapel Hill, NC

Videos

Management of Older Patients With Breast Cancer

03/17/2023

Hyman Muss, MD, outlines the important considerations for providers caring for older patients with breast cancer.

Hyman Muss, MD, outlines the...

03/17/2023

Oncology

Hyman Muss, MD, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

Videos

Delivering Effective End-of-Life Care for Patients With Breast Cancer

03/17/2023

Hyman Muss, MD, details his best practices for delivering effective end-of-life care for patients with breast cancer.

Hyman Muss, MD, details his best...

03/17/2023

Oncology

Kelly Hunt, MD, MD Anderson Cancer Center, Houston, TX

Videos

Axillary Reverse Mapping: Preventing Lymphedema Among Patients With Breast Cancer

03/16/2023

Kelly Hunt, MD, discusses the practice of axillary reverse mapping in the prevention of lymphedema for patients with breast cancer.

Kelly Hunt, MD, discusses the...

03/16/2023

Oncology

Videos

Metronomic Chemotherapy for Patients With Breast Cancer

03/16/2023

Dr Hyman Muss offers his insights on how metronomic chemotherapy can fit into the treatment paradigm for patients with breast cancer.

Dr Hyman Muss offers his...

03/16/2023

Oncology

Ruth O’Regan, MD, University of Rochester, NY

Videos

Breast Cancer Index Assay to Select for Ovarian Suppression in Premenopausal Women With HR-Positive Breast Cancer

01/31/2023

At the 2022 San Antonio Breast Cancer Symposium, Ruth O’Regan, MD, presented updated data from the SOFT trial, investigating the predictive potential of the breast cancer index assay in determining which premenopausal patients with...

At the 2022 San Antonio Breast...

01/31/2023

Oncology

Arielle Medford, MD, Dana-Farber Cancer Institute, Boston, MA

Videos

Monitoring for Circulating Tumors DNA to Select for Adjuvant Therapy Escalation Among Patients With HR-Positive/HER2-Negative Breast Cancer

01/30/2023

At the 2022 San Antonio Breast Cancer Symposium, Arielle Medford, MD, discusses results from the ongoing LEADER trial, investigating the efficacy of adjuvant endocrine therapy plus CDK4/6 inhibitor ribociclib for HR-positive, HER2-negative...

At the 2022 San Antonio Breast...

01/30/2023

Oncology

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA

Videos

Talazoparib for Patients With Somatic BRCA-Mutant Metastatic Breast Cancer

01/26/2023

At the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, discusses the ongoing phase 2 trial evaluating the efficacy of talazoparib for patients with BRCA-mutant, HER2-negative metastatic breast cancer.

At the 2022 San Antonio Breast...

01/26/2023

Oncology

Cynthia Ma, MD, PhD, Washington University, St. Louis, MO

Videos

Selecting Neoadjuvant Therapy for HR-Positive Breast Cancer

01/26/2023

At the 2022 San Antonio Breast Cancer Symposium, Cynthia Ma, MD, PhD, discusses the neoadjuvant therapy options available for patients with HR-positive breast cancer.

At the 2022 San Antonio Breast...

01/26/2023

Oncology

Ariella Hanker, PhD, UT Southwestern Medical Center, Dallas, TX

Videos

Biological Mechanisms of CDK4/6 Inhibitor Resistance

01/24/2023

At the 2022 San Antonio Breast Cancer Symposium, Ariella Hanker, PhD, discusses the biological mechanisms behind CDK4/6 inhibitor resistance and novel approaches being developed to overcome this resistance in patients with breast cancer.

At the 2022 San Antonio Breast...

01/24/2023

Oncology

Ruth O'Regan, MD, University of Rochester

Videos

Debate: Are All CDK4/6 Inhibitors the Same?

01/23/2023

At the 2022 San Antonio Breast Cancer Symposium, Ruth O'Regan, MD, participated in the debate, “Are All CDK4/6 Inhibitors the Same or Different?” in which she took the position that they are different.

At the 2022 San Antonio Breast...

01/23/2023

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology